Date: 2016-01-10
Type of information: Nomination
Compound:
Company: Freeline Therapeutics (UK)
Therapeutic area: Hematologic diseases - Genetic diseases - Rare diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 10, 2016, Freeline Therapeutics, a biopharmaceutical company focused on the development of gene therapies for bleeding and other debilitating disorders, announced that Jan Thirkettle, former VP, Cell & Gene Therapy Platform at GSK, has been appointed Chief Development Officer and Gerard Short, former Senior Medical Director at Genzyme Corporation, has been appointed SVP, Head of Clinical and Regulatory. Freeline, based at the Royal Free Hospital, London, was launched in December 2015 with a £25 million Series A financing from Syncona LLP. Dr Jan Thirkettle joins Freeline from GSK where he was VP, Cell & Gene Therapy Platform. In this capacity, over the period of 4 years, he built GSK’s Chemistry, Manufacturing and Control (CMC)/supply capabilities in the cell & gene therapy field, enabling the submission of a Marketing Authorisation Application (MAA) for an ex vivo gene therapy for ADA-SCID in 2015 and establishment of a portfolio of technologies and programmes. Prior to this, Jan was responsible for CMC and supply of a number of late/launch stage biopharmaceuticals. Jan holds an MA in Chemistry and a PhD in Biological Chemistry from Oxford University. Dr Gerard Short joins Freeline from Genzyme Corporation where he was the global clinical development lead for Genzyme’s Pompe’s Disease programme, including Myozyme/ Lumizyme and the second generation enzyme replacement therapy, NeoGAA. Prior to that he was the global clinical development lead for clofarabine, a treatment for relapsed refractory Acute Lymphoblastic Leukaemia in children. Ged is a pharmaceutical physician with close to 18 years’ experience of pharma and biotech. He qualified in Medicine at St Mary’s Hospital Medical School at the University of London; is a Fellow of the Faculty of Pharmaceutical Medicine and has an MBA from London Business School.
Financial terms:
Latest news:
